Experimental cocktail aims to outsmart tough lung cancer

NCT ID NCT07531095

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This early-phase trial is testing whether combining two experimental drugs, tarlatamab and ZL-1310, with or without the immunotherapy durvalumab, can safely shrink tumors in people with small cell lung cancer that has worsened after standard treatment. About 160 adults will take part to find the best dose and check for side effects. The goal is to see if this mix can control the disease longer than current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tarlatamab (a drug) combined with ZL-1310 (another drug), with or without durvalumab (an immunotherapy)
What this could lead to: If successful, this could point toward a new combination treatment for small cell lung cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is an early Phase 1 study with only 160 participants, so safety and the right dose are still being figured out. The combination may cause serious side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Adana Sehir Egitim ve Arastirma Hastanesi
RECRUITING

Adana, 01370, Turkey (Türkiye)
Baptist Cancer Center
RECRUITING

Memphis, Tennessee, 38120, United States
City of Hope Cancer Center Phoenix
RECRUITING

Goodyear, Arizona, 85338, United States
City of Hope Chicago
RECRUITING

Zion, Illinois, 60099, United States
Gustave Roussy
RECRUITING

Villejuif, 94805, France
Hacettepe Universitesi Tip Fakultesi Hastanesi
RECRUITING

Ankara, 06230, Turkey (Türkiye)
Health Partners Cancer Center at Regions Hospital
RECRUITING

Saint Paul, Minnesota, 55101, United States
Hopital de la Timone
RECRUITING

Marseille, 13005, France
Hospital Clinico Universitario Virgen de la Victoria
RECRUITING

Málaga, Andalusia, 29010, Spain
Hospital Clinico Universitario de Valencia
RECRUITING

Valencia, Valencia, 46010, Spain
Hospital Universitari Vall d Hebron
RECRUITING

Barcelona, Catalonia, 08035, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Ramon y Cajal
RECRUITING

Madrid, 28034, Spain
Izmir Ekonomi Universitesi Medical Point Hastanesi
RECRUITING

Izmir, 35575, Turkey (Türkiye)
Kantonsspital Sankt Gallen
RECRUITING

Sankt Gallen, 9007, Switzerland
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
RECRUITING

Gliwice, 44-102, Poland
New York University Cancer Institute
RECRUITING

New York, New York, 10016, United States
Next Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Universitaetsklinikum Dresden
RECRUITING

Dresden, 01307, Germany
Universitaetsklinikum Wuerzburg
RECRUITING

Würzburg, 97078, Germany
Universitair Ziekenhuis Gent
RECRUITING

Ghent, 9000, Belgium
Uniwersyteckie Centrum Kliniczne
RECRUITING

Gdansk, 80-214, Poland
Ziekenhuis aan de Stroom Augustinus
RECRUITING

Wilrijk, 2610, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.